Why the study?
Randomized controlled trials are subject to bias without methodological quality, and optimal reporting aids critical appraisal, prompting an evaluation of reporting quality in NOAC trials for AF.
The reporting quality of RCTs evaluating NOACs for atrial fibrillation remains unsatisfactory despite the 2010 CONSORT statement, highlighting the need for stricter adherence to reporting guidelines to prevent misleading clinical decisions.
Answers are grounded in this paper and cite their sources.
Suboptimal reporting persists in NOAC AF RCTs; supports mandatory CONSORT adherence to improve trial interpretability.
Background: Randomized controlled trials (RCTs) are subject to bias if they lack methodological quality. Furthermore, optimal and transparent reporting of RCT findings aids their critical appraisal and interpretation. This study aimed to comprehensively evaluate the report quality of RCTs of non-vitamin K oral anticoagulants (NOACs) for the treatment of atrial fibrillation (AF) and to analyze the factors influencing the quality. Methods: By searching PubMed, Embase, Web of Science, and Cochrane Library databases RCTs published from inception to 2022 evaluating the efficacy of NOACs on AF were collected. By using the 2010 Consolidated Standards for Reporting Tests (CONSORT) statement, the overall quality of each report was assessed. Results: Sixty-twoRCTs were retrieved in this study. The median of overall quality score in 2010 was 14 (range: 8.5-20). The extent of compliance with the Consolidated Standards of Reporting Trials reporting guideline differed substantially across items: 9 items were reported adequately (more than 90%), and 3 were reported adequately in less than 10% of trials. Multivariate linear regression analysis showed that the higher reporting scores were associated with higher journal impact factor (P = 0.02), international collaboration (P < 0.01), and Sources of trial funding (P = 0.04). Conclusions: Although a large number of randomized controlled trials of NOACs for the treatment of AFwere published after the CONTORT statement in 2010, the overall quality is still not satisfactory, thus weakening their potential utility and may mislead clinical decisions. This survey provides the first hint for researchers conducting trials of NOACs for AF to improve the quality of reports and to actively apply the CONSORT statement.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: